Breast cancer stem cells: Features, key drivers and treatment options
Breast cancer stem cells: Features, key drivers and treatment options
复制标题
DOI：
10.1016/j.semcancer.2018.07.007
复制
发表时间：
2018-12-01
影响因子：
14.5
通讯作者：
Dittmer, Juergen
中科院分区：
文献类型：
--
作者：
Dittmer, Juergen
目前的观点是，乳腺癌是一种干细胞疾病，其特征是存在具有干细胞样特征和肿瘤引发潜力的癌细胞。这些细胞负责肿瘤的传播和转移。通过化疗药物的常见疗法不能根除这些细胞，而是增加肿瘤中的癌干细胞库，这种作用可能增加复发的可能性。15年后的第一个证据，一个小的干细胞样亚群在乳腺癌的发生中发挥了重要作用，已经出版了大量的知识积累有关的信号级联和蛋白质参与维持乳腺癌的干性。在不同的乳腺癌亚型中，干细胞池的大小和调节干细胞的机制存在差异。总的来说，这些知识提供了干预乳腺癌干细胞活性的新方法。对于三阴性乳腺癌亚型的治疗，特别需要新的选择，三阴性乳腺癌亚型特别富含癌症干细胞，也是仍然没有特定疗法的亚型。
The current view is that breast cancer is a stem cell disease characterized by the existence of cancer cells with stem-like features and tumor-initiating potential. These cells are made responsible for tumor dissemination and metastasis. Common therapies by chemotherapeutic drugs fail to eradicate these cells and rather increase the pool of cancer stern cells in tumors, an effect that may increase the likelyhood of recurrence. Fifteen years after the first evidence for a small stem-like subpopulation playing a major role in breast cancer initiation has been published a large body of knowledge has been accumulated regarding the signaling cascades and proteins involved in maintaining sternness in breast cancer. Differences in the stern cell pool size and in mechanisms regulating sternness in the different breast cancer subtypes have emerged. Overall, this knowledge offers new approaches to intervene with breast cancer stern cell activity. New options are particularly needed for the treatment of triple-negative breast cancer subtype, which is particularly rich in cancer stem cells and is also the subtype for which specific therapies are still not available.